Kaynak: MarketBeat
Haber Ajansı
Hisse Senedi
Orta Önem
Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.
İlgili Semboller
1
R
RCUS
RCUS
Kaynak: MarketBeat
Kaynağı Ziyaret Et